(Total Views: 478)
Posted On: 05/14/2020 5:03:15 PM
Post# of 72445
https://www.sunovion.us/partnering/
If B is shown to help lung tissue, there is now doubt in my mind that what I’ve heard is right. Sunovion, Sumitumo’s subsidiary is in the market for a phase 3 respiratory drug. IPIX sits right next door to them holding B.
Sunovion has inhaler/nebulizer technology used for Brovana it’s COPD medicine who’s patent ends Nov. 2021 and generic entries begin. If we look at timing this lines up exactly as it would seem and makes total sense and they could transition to an inhaled B and hold many more years of patent life than that for Brovana.
If B is shown to help lung tissue, there is now doubt in my mind that what I’ve heard is right. Sunovion, Sumitumo’s subsidiary is in the market for a phase 3 respiratory drug. IPIX sits right next door to them holding B.
Sunovion has inhaler/nebulizer technology used for Brovana it’s COPD medicine who’s patent ends Nov. 2021 and generic entries begin. If we look at timing this lines up exactly as it would seem and makes total sense and they could transition to an inhaled B and hold many more years of patent life than that for Brovana.
(4)
(0)
